Bcl-2 inhibitor overcomes drug resistance to 5-fluorouracil in Huh-7 pre-S2Δ cells, which provides a new approach to the combinational therapy of HBV pre-S2Δ large surface protein-related HCC. This evidence concerns the gene BCL2 and hepatocellular carcinoma.